Preclinical reports have shown PI3K inhibitors such as PIK75 and PF-4989216 to have activity in SCLC models with PIK3CA mutations, but not PTEN deficiency, indicating a possible role for PI3K/mTOR-targeted therapy in SCLC [11, 12]. Here, PTEN is linked to small cell lung carcinoma.